Log in to save to my catalogue

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENS...

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENS...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1835535233

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

About this item

Full title

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2016-10, Vol.388 (10055), p.1995-2003

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy. Few safety data about edoxaban in patients undergoing electrical cardioversion are available. Methods We did a multi...

Alternative Titles

Full title

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1835535233

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1835535233

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(16)31474-X

How to access this item